Dysport and Daxxify are both FDA approved botulinum toxin type A injections for frown lines. Dysport is the older, broader spreading, cheaper per session option; Daxxify is peptide stabilized and held results a median of about 24 weeks, close to six months, in its trials. Compare formulation, onset, duration, FDA approvals, safety, honest cost ranges and how to choose, clinician reviewed.
Dysport and Daxxify are both FDA approved botulinum toxin type A injections for frown lines. Dysport starts working in about 2 to 3 days and spreads more widely. Daxxify held results for a median of roughly 6 months in trials, versus about 3 to 4 months for Dysport.
Dysport and Daxxify sit on the same shelf and do the same job. Both are purified botulinum toxin type A, both are injected into the small muscles that fold the skin between your brows, and both work by blocking the nerve signal that tells those muscles to contract. Relaxed muscle means a flatter, calmer surface, and the lines that only appear when you frown soften first. Nothing about either product fills a line, plumps tissue or changes skin quality. If your frown line is etched in at rest, neither will erase it on its own.
The reason people compare these two specifically is that they represent opposite ends of the neuromodulator market. Dysport, approved in the United States in 2009, is the established, widely stocked, lower cost per session option with a large body of clinical and real world experience behind it. Daxxify, approved in September 2022, is the newest entrant and the only botulinum toxin formulated with a stabilizing peptide instead of human serum albumin. Its pitch is duration: in its pivotal trials, the median time for frown lines to return to moderate or severe was around 24 weeks. That is a genuinely different value proposition, and it is also the claim that deserves the closest reading.
FDA status, stated plainly. Dysport (abobotulinumtoxinA) is FDA approved for the temporary improvement of moderate to severe glabellar (frown) lines in adults under 65, for cervical dystonia in adults, and for spasticity in patients aged 2 and older. Daxxify (daxibotulinumtoxinA-lanm) is FDA approved for moderate to severe glabellar lines in adults and for cervical dystonia in adults. Every other cosmetic area either product is used for, including forehead lines, crow's feet, bunny lines, lip flip, gummy smile, masseter slimming, neck bands and underarm sweating with these particular brands, is off-label. Off-label prescribing is legal and routine in aesthetic medicine, but it should be named out loud rather than glossed over. Both products carry an FDA boxed warning about distant spread of toxin effect. This is educational content, not medical advice.
The honest headline is that these two products produce very similar looking results in the same treated area. Head to head randomized trials comparing Dysport directly against Daxxify have not been published, so anyone claiming one visibly outperforms the other is reasoning from separate trials run against placebo, not from a direct contest. What differs, and differs in ways you can actually feel and budget for, is the formulation, the diffusion pattern, the expected time between appointments and the price per visit. Dysport is stabilized with human serum albumin and lactose and spreads more broadly from each injection point. Daxxify is stabilized with a 35 amino acid peptide, contains no human or animal derived protein, and was engineered specifically for a longer interval between treatments. Both are injected in a ten minute appointment with no downtime, both take about two weeks to reach full effect, and neither can be undone once placed. The table below sets out the head to head attributes the rest of this guide explains, and every figure in it is drawn from the two prescribing informations or the published phase 3 trials rather than from marketing copy.
| Attribute | Dysport | Daxxify |
|---|---|---|
| Active ingredient | abobotulinumtoxinA | daxibotulinumtoxinA-lanm |
| Manufacturer | Ipsen, marketed for aesthetics in the US by Galderma | Revance Therapeutics, a Crown Laboratories company |
| First US approval | 2009 | September 2022 |
| FDA approved cosmetic use | moderate to severe glabellar (frown) lines, adults under 65 | moderate to severe glabellar (frown) lines, adults |
| Other FDA approvals | cervical dystonia in adults, spasticity in patients 2 and older | cervical dystonia in adults |
| Stabilizer | human serum albumin plus lactose, contains trace cow's milk protein | RTP004 peptide, no human serum albumin, no lactose |
| Label dose for frown lines | 50 Units total, 10 Units at each of 5 sites | 40 Units total, 8 Units at each of 5 sites |
| Onset | commonly 2 to 3 days | commonly 2 to 3 days, full effect around 2 weeks |
| Duration for frown lines | about 3 to 4 months | median about 24 weeks to return to moderate or severe |
| Diffusion | broader spread from each point | comparatively contained |
| Boxed warning | distant spread of toxin effect | distant spread of toxin effect |
| Units | brand specific, not interchangeable with any other toxin | brand specific, not interchangeable with any other toxin |
| Reversible | no, wears off over time | no, wears off over time |
| Typical US price per frown line treatment | roughly $300 to $600 | roughly $500 to $1,000 |
| Availability | stocked almost everywhere | less widely stocked |
| Best suited to | fast, familiar, lower cost per visit | fewer appointments per year |
Start with the overlap, because it is larger than the marketing implies. Both are botulinum toxin type A, the same serotype used in Botox, Xeomin and Jeuveau. Both are acetylcholine release inhibitors: the toxin cleaves a protein the nerve ending needs in order to release its signalling chemical, so the muscle receives no instruction to contract. The effect is temporary because the nerve terminal regenerates over months. Neither dissolves, neither can be reversed, and neither is removed once injected. If you dislike the result, the only remedy is time, which is a genuine consideration when one of the two is designed to last longer.
Both are prescription only biologics that must be reconstituted from a lyophilized powder with preservative free saline and injected by a licensed medical professional. Both are supplied in brand specific potency Units, and both labels state explicitly that those Units are not interchangeable with any other botulinum toxin preparation. Fifty Dysport Units and 40 Daxxify Units are each a full label dose for frown lines, but they are not the same quantity of anything, which is why comparing brands on a per unit price is meaningless.
Both carry the same FDA boxed warning: the effects of the toxin can spread beyond the injection site and cause symptoms including swallowing and breathing difficulty, which can be life threatening. That warning applies to the whole class. Serious distant spread has been reported overwhelmingly in high dose therapeutic use, not at the small cosmetic doses used between the brows, but it belongs on the page rather than in a footnote. Both are also contraindicated with infection at the intended injection site and with known hypersensitivity to any botulinum toxin product.
The formulation difference is real and not cosmetic. Each Dysport vial contains human serum albumin, a blood derived protein used to stop the tiny amount of toxin sticking to the glass, plus lactose. Because lactose is milk derived, the Dysport label lists allergy to cow's milk protein as an outright contraindication. Daxxify replaces albumin with RTP004, a positively charged 35 amino acid peptide that performs the same anti adsorption and thermal stability role, so the vial contains no human or animal derived material and no lactose. For most people this is a technical footnote. For someone with a milk protein allergy it is the deciding factor.
On speed, the gap is smaller than the internet suggests. Dysport is widely reported to show early effect at around 2 to 3 days, and its broader diffusion means smoothing can appear to arrive evenly across a wide zone. Daxxify's trials reported a median onset of roughly 2 days, some participants noticing change within 24 hours, though the prescribing information describes effects manifesting over one to two weeks. Both peak at roughly 14 days, and judging either before that mark is the most common patient mistake.
Duration is where the products actually separate, and it deserves a careful reading. In the SAKURA 1 and SAKURA 2 phase 3 trials published in Plastic and Reconstructive Surgery, Daxxify held frown lines at none or mild severity for a median of 24.0 and 23.9 weeks, with a median of 26.0 to 27.7 weeks before returning to baseline. Median means half of participants returned sooner. Dysport's glabellar duration is generally described as about 3 to 4 months. Daxxify is therefore longer on average, but six months is a midpoint, not a promise, and individual duration swings with dose, muscle strength, metabolism and treatment area.
The approved cosmetic indication for both products is narrow and identical in substance: the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and procerus muscle activity. That is the vertical frown lines between the eyebrows, and nothing else. Dysport adds an age ceiling that Daxxify does not, since its cosmetic indication is written for adult patients under 65 years of age. Neither is approved for anyone under 18 for cosmetic use.
On the therapeutic side, Dysport has the broader label by a wide margin. It is approved for cervical dystonia in adults and for spasticity in patients aged 2 years and older, covering both upper and lower limb spasticity in adults and children. Daxxify holds a single therapeutic approval, for cervical dystonia in adults, granted in 2023. That breadth matters less for a cosmetic decision than it does for the depth of safety data behind each product, where Dysport's longer and wider exposure is a genuine advantage.
Everything else you may have been offered with either brand is off-label. Forehead lines, crow's feet, brow lift, bunny lines, lip flip, gummy smile, chin dimpling, platysmal neck bands, masseter reduction and excessive underarm sweating are all treated with these toxins in practice, and several are supported by reasonable published evidence, but none appears on the Dysport or Daxxify label. Off-label does not mean unsafe or improper. It means the manufacturer has not run the trials required to add that indication, so dosing and technique rest on clinical judgment rather than an approved protocol. A trustworthy injector names the category before you agree to treatment.
Dysport tends to suit people treating a broad, relatively flat area and anyone who wants a lower financial commitment per visit. Its wider diffusion from each injection point can smooth a large forehead with fewer punctures and a more even transition, which is one reason experienced injectors reach for it in that zone. It is also the sensible starting point if you have never used a neuromodulator, because a result you dislike resolves in roughly 3 to 4 months rather than lingering. Dysport is stocked almost universally, so your choice of provider is unrestricted.
Daxxify makes most sense for someone who has already used a toxin, knows they like the result and their dosing, and simply wants fewer appointments. Two visits a year instead of three or four is a real convenience for frequent travellers or anyone who dislikes the fade and refill cycle. It is also the option for a patient with a cow's milk protein allergy, who is contraindicated for Dysport. Some clinicians consider it for patients who responded poorly or briefly to other toxins, although evidence for that use is limited rather than settled.
There is no ideal age for either product, despite how often that question is asked. Both are prescription treatments for adults, so 18 is the practical floor, and Dysport's cosmetic indication is written for adults under 65 while Daxxify's carries no upper age limit. In practice most people start when a frown line has begun to linger after the face relaxes, which for many falls somewhere between the late twenties and the forties, but that is a pattern rather than a rule. Whether treating early prevents a line from etching in permanently is plausible and widely claimed, yet it has not been settled by long term controlled evidence, so it should be presented as a reasonable expectation rather than a proven outcome. At the other end, a crease that is deeply etched at rest usually needs resurfacing, filler or skin quality treatment alongside the toxin, because relaxing the muscle cannot flatten a fold that has become structural.
Neither product is appropriate during pregnancy or breastfeeding, since neither has been studied in those groups. Both should be avoided by anyone with a neuromuscular disorder such as myasthenia gravis, Lambert Eaton syndrome or ALS, which can amplify the effect of the toxin. Tell your injector about aminoglycoside antibiotics, muscle relaxants and anticoagulants, and about any previous toxin treatment that did not work, since a small number of people develop neutralizing antibodies. Marked eyelid or brow ptosis, and unrealistic expectations about lines etched in at rest, are reasons to reconsider or combine treatments rather than proceed on toxin alone.
The common side effects are shared and mostly minor. Expect the possibility of injection site pain, redness, swelling, small bruises and a headache in the first day or two. In the Daxxify phase 3 trials, headache occurred in roughly 6 to 7 percent of treated participants and injection site pain in roughly 2 to 5 percent. Dysport's cosmetic trials report a similar profile, with nasopharyngitis, headache, injection site pain and eyelid swelling among the events listed. Most settle without treatment within days.
The side effect people actually worry about is droop. Eyelid ptosis, a heavy or hooded upper lid, and brow ptosis, a flattened or lowered brow, happen when toxin reaches the levator or frontalis muscle beyond the intended target. Both products can cause it, both report it at low single digit rates in cosmetic trials, and it is largely a function of dose, placement and individual anatomy rather than of brand. It resolves only as the product wears off, which is precisely where Daxxify's longer duration cuts against it: an unwanted result on a six month product takes longer to outlast. Double vision, dry eye and an uneven smile are less common but reported.
The serious risk on both labels is distant spread of toxin effect, meaning swallowing difficulty, slurred speech, generalized muscle weakness or breathing problems occurring hours to weeks after injection. This is rare at cosmetic doses and has been reported mainly at the much higher doses used therapeutically. Seek urgent medical care for any swallowing or breathing difficulty after treatment. Two practical points apply to both brands: insist on a licensed medical injector working in a clinical setting, and be sceptical of unusually cheap treatment, since the FDA has warned about counterfeit and unlicensed botulinum toxin products causing botulism like illness. Neither product is proven safer than the other, and the operator matters more than the label.
Real pricing varies too much for any figure here to function as a quote. Across the United States, a full label frown line treatment with Dysport commonly lands somewhere in the region of $300 to $600, while the same treatment with Daxxify commonly runs roughly $500 to $1,000. Those are broad ranges rather than rates, and they move with region, injector credentials, practice type, whether the clinic charges per unit or per area, and how much product your anatomy actually needs. Only a consultation produces a real number.
The trap in every Dysport versus Daxxify price comparison is the per unit figure. Dysport is usually quoted per unit, often a few dollars each, which looks dramatically cheaper than a per unit Daxxify or Botox quote. It is not a like for like number. Dysport Units and Daxxify Units are measured by different assays and are not convertible, and a full label frown line dose is 50 Units of Dysport against 40 Units of Daxxify. Comparing brands per unit is like comparing currencies without an exchange rate. The only meaningful comparisons are cost per treated area and cost per year.
Run the annual arithmetic before deciding. Dysport at three treatments a year in the middle of its range costs broadly what Daxxify costs at two treatments a year, so the yearly gap is often far smaller than the sticker shock suggests, and for some patients it closes entirely. Where the maths breaks down is if Daxxify gives you four or five months rather than six, since half of trial participants came in below the median. Ask for the total treatment price rather than a per unit rate, and whether a two week review and any touch up are included. Manufacturer loyalty programs shift the effective price in ways that never appear on a posted price list.
The verdict most comparison pages avoid is that there is no winner. Both are FDA approved for the same cosmetic indication, both work by the same mechanism, both carry the same class warning, and neither has been shown superior in a published head to head trial. The rational way to choose is by constraint rather than by claim. If cost per visit, universal availability, a broad diffusion pattern for a wide forehead or a short commitment on your first ever treatment matters most, Dysport is the sensible pick. If appointment frequency is what you want to fix, or you have a milk protein allergy, Daxxify has the stronger case.
Then apply the rule that outranks the product decision entirely. Neuromodulator results are produced by dose, injection point, depth and an accurate read of how your particular muscles pull, and any of those judgments can be got wrong with either vial. A skilled injector will watch you frown, raise your brows and smile before touching a syringe, will explain why they are proposing a particular number of Units in particular spots, and will undertreat rather than overtreat a first appointment. That last habit is worth more than any brand preference.
Ask a short list of questions at consultation. Which product are you recommending and why that one for me. Is my treatment area on-label or off-label. How many Units, and what is the total price rather than the per unit price. Is a two week review included, and what happens if I get a droop. Who exactly is injecting, what is their license, and who supervises them. Ask to see their own before and after photographs of your specific area, not manufacturer stock images. A good injector will tell you when the honest answer is a lower dose, a different product or no toxin at all. When you are ready, the next step is finding a licensed, qualified injector near you.
No published head to head trial compares them, so nobody can claim one works better. Both are FDA approved botulinum toxin type A and smooth frown lines by the same mechanism. Daxxify lasted longer in its own trials, a median of about 24 weeks against roughly 3 to 4 months for Dysport. Onset and appearance are comparable.
It costs more per treatment, is stocked in fewer clinics, and has less real world track record than toxins approved a decade or more earlier. The six month figure is a median, so half of trial participants faded sooner. And because nothing reverses a neuromodulator, an unwanted droop takes longer to wear off on a longer acting product.
Usually meaningfully more per visit, though no fixed markup exists and pricing varies widely by provider and region. Broadly, a frown line treatment runs roughly $300 to $600 with Dysport and roughly $500 to $1,000 with Daxxify. Per year the gap narrows, since Daxxify may need two visits where Dysport needs three.
Neither is proven safer. Both are botulinum toxin type A, both carry the same FDA boxed warning about distant spread of toxin effect, and both report similar mild side effects such as headache, bruising and occasional eyelid or brow droop. Daxxify contains no albumin or lactose, which matters for a milk protein allergy but does not make it inherently safer.
At common US per unit pricing, 20 Dysport Units often runs roughly $80 to $200, though rates vary widely by provider and region. Note that 20 Units is well below the label dose: a full frown line treatment is 50 Dysport Units. Dysport Units are not equivalent to Daxxify, Botox or Xeomin Units.